Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas
Hongyi Li, Jian Tu, Zhiqiang Zhao, Lijuan Chen, Yueting Qu, Hongbo Li, Hao Yao, Xiaoshuai Wang, Dung‐Fang Lee, Jingnan Shen, Lili Wen, Gang Huang, Xianbiao Xie
Abstract
BRCAness might be the common genomic and molecular characteristics of majority of STS cases. PARP-1 and PAR could be potential proper and feasible theranostic biomarkers for assessing HRD in patients. STSs were sensitive to PARPi. Moreover, the combination of niraparib and TMZ showed synergistic effect. Niraparib and TMZ could be a promising targeted therapeutic strategy for patients with STS.
Topics & Concepts
Soft tissueCancer researchPARP inhibitorBiologyPathologyComputational biologyPoly ADP ribose polymeraseMedicineDNAGeneticsPolymerasePARP inhibition in cancer therapyCAR-T cell therapy researchIntegrated Circuits and Semiconductor Failure Analysis